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Abstract
Background: The variation of the most common Human papillomavirus (HPV) type found in cervical cancer, the HPV16, has
been extensively investigated in almost all viral genes. The E1 gene variation, however, has been rarely studied. The main
objective of the present investigation was to analyze the variability of the E6 and E1 genes, focusing on the recently
identified E1-1374ˆ63nt variant.
Methodology/Principal Findings: Variation within the E6 of 786 HPV16 positive cervical samples was analyzed using high-
resolution melting, while the E1-1374ˆ63nt duplication was assayed by PCR. Both techniques were supplemented with
sequencing. The E1-1374ˆ63nt duplication was linked with the E-G350 and the E-C109/G350 variants. In comparison to the
referent HPV16, the E1-1374ˆ63nt E-G350 variant was significantly associated with lower grade cervical lesions (p = 0.029),
while the E1-1374ˆ63nt E-C109/G350 variant was equally distributed between high and low grade lesions. The E1-1374ˆ63nt
variants were phylogenetically closest to E-G350 variant lineage (A2 sub-lineage based on full genome classification). The
major differences between E1-1374ˆ63nt variants were within the LCR and the E6 region. On the other hand, changes within
the E1 region were the major differences from the A2 sub-lineage, which has been historically but inconclusively associated
with high grade cervical disease. Thus, the shared variations cannot explain the particular association of the E1-1374ˆ63nt
variant with lower grade cervical lesions.
Conclusions/Significance: The E1 region has been thus far considered to be well conserved among all HPVs and therefore
uninteresting for variability studies. However, this study shows that the variations within the E1 region could possibly affect
cervical disease, since the E1-1374ˆ63nt E-G350 variant is significantly associated with lower grade cervical lesions, in
comparison to the A1 and A2 sub-lineage variants. Furthermore, it appears that the silent variation 109T.C of the E-C109/
G350 variant might have a significant role in the viral life cycle and warrants further study.
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Introduction
Human papillomaviruses (HPV) are small, double stranded
DNA viruses. Even though there exist more than 100 different
genotypes, only about 40 infect the human anogenital tract. At
least 13 oncogenic or high-risk HPV types are involved in the
development of neoplasia and cancer, notably cervical cancer [1].
The HPV types themselves are subdivided into viral variants,
which themselves have been shown to have differing oncogenic
potential [2].
HPV16 is the most prevalent HPV type in cervical cancer cases
worldwide [3] and is also the most prevalent HPV type in other
lesions [4]. Many studies have focused on HPV16 variability in
different regions of the HPV genome, mostly the E6 and E7
oncogenes [5]. The variability of the E2 and late genes, L1 and L2,
along with the long control region (LCR), has also been analyzed
[6]. Studies focusing on E1 region, however, are limited.
Previously we found a 63-nucleotide duplication, at position
1374 within the E1 gene (E1-1374 6ˆ3nt), in about 10% of HPV16
positive cervical samples. This finding indicates that this particular
variation is relatively common in the Croatian population [7], and
possibly elsewhere. The same variant was also confirmed to be
present in neighbouring Slovenia, in about 8% of samples [8]. The
HPV16 variant containing this duplication was more strongly
linked with low-grade cervical lesions than the reference HPV16
(E–r; European prototype) [7]. Furthermore, all samples contain-
ing the E1-1374 6ˆ3nt duplication belonged to the commonly
reported E-G350 (E6-350G or L83V) variants [7]. The E-G350
variant is still controversial in terms of its oncogenicity, which has
been found to vary significantly across different studies [5].
The first goal of this study was to analyze the variability of the
E6 gene together with the E1 gene, focusing on the recently
identified E1-1374 6ˆ3nt variant. The second objective was to
evaluate the association of the E1-1374 6ˆ3nt variant with different
grades of cervical lesions on a large number samples in order to
clarify the association of this variant with lower grade cervical
lesions. In this study, we focused on E6 region to eliminate the
possibility that the previously known HPV16 E6 variants affect this
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association. The final goal was to determine if nucleotide changes
in other regions of the HPV16 genome might be responsible for
the observed association. For this reason we sequenced the whole
genome of this E1 variant.
Materials and Methods
DNA Collection
In this study, 786 individual HPV16 positive archival DNA
samples of cervical smears collected and stored in the local DNA
Biobank from 1999 to 2009 at the Division of Molecular Medicine
(Rudjer Boskovic Institute, Zagreb, Croatia) were analyzed. HPV
detection and genotyping was done with two consensus primer
sets, MY09/11 (up to 2006, PGMY09/11 thereafter) and L1C1,
and type-specific primers for HPV types 6/11, 16, 18, 31, 33, 45,
52 and 58, as previously described by Milutin-Gasperov et al. [9].
When available, patient cytological diagnosis was used for
statistical analysis [10]. Average age of examinees was 29.1 (11-
69).
Ethics Statement
Verbal patient consent was obtained for each cervical specimen
that was collected for HPV diagnostic and research purposes.
Direct written consent was not required. Namely, the cervical
sample collection is regulated through Laboratory service request
forms, which have to be signed and approved by the practicing
physician. These forms serve to document the indirect consent of
each patient. Both the DNA extracted from cervical specimens
and the relevant patient data (age, cytological diagnosis, HPV
detection and typing result), were processed anonymously. The
study was funded by the Croatian Ministry of Science, Education
and Sport, through Research Grant No. 098-0982464-2510, and
approved by the Ethical Board of the Rudjer Boskovic Institute
(Zagreb) as well as the Ethical Board of the "Sisters of Mercy"
Hospital (Zagreb) and is in line with the Helsinki declaration
(DoH/Oct2008).
E6 Variants Analysis
The high resolution melting (HRM) method was used to
determine HPV16 variability, as described previously [11]. Briefly,
primers designed by Ortiz et al. [12] and Sotlar et al. [13] were
adapted to be used in the nested polymerase chain reaction (PCR)
[11]. The inner PCR was performed in the presence of the double-
stranded-DNA-binding fluorescent dye LCgreen+ and the fluo-
rescence emission during the sample heating was recorded on the
HR1 instrument (Idaho Technologies, USA). The resulting
melting curves were compared to the melting curves of simulta-
neously run reference samples within the HR1 software and the
deviations indicated E6 region variants.
E6 Variant Sequencing
Samples with melting curves that differed from the reference
were sequenced after amplicon purification using Promega
Wizard(R) SV Gel and PCR Clean-Up System (Promega, USA).
Ten randomly selected reference (E-r) and ten randomly selected
E-G350 variants were sequenced for assay verification. Samples
were sequenced using both forward and reverse primers on the
3730xl DNA Analyzer (Applied Biosystems, USA) at the European
Hospital Georges Pompidou, Paris, France.
E1 Duplication Analysis
The E1-1374 6ˆ3nt duplication was detected using specific
primer directed PCR for the E1 region, as described previously
[14]. Briefly, primers that amplify 189 bp of the E1 region were
used. If the duplication is present then the E1 amplicon is shifted
to around 250 bp.
Whole Genome Sequencing
The HPV genome of two randomly selected samples of the E1-
1374 6ˆ3nt E-G350 variant and two additional randomly selected
samples of the E1-1374 6ˆ3nt E-C109/G350 variant were
completely sequenced using primers and conditions from the
study by Bhattacharjee et al. [15] with additional modifications.
Thus, several additional primer pairs were used for the sequencing
of the E1 region: E1-A1 (5’-CTCAGAAACCATAATCTACC)
with E1–B2 (5’-CTAATAGTAACACAACCATTCC), E1–A2
(5’-CAAAGTTTAGCATGTTCATGG) with E1–B4 (5’-GTAG-
CATCATCTAACATACC), E1–A3 (5’-CACAGGCAAAAA-
TTGTAAAGG) with E1–B5 (5’-GTCTATATGGTCACG-
TAGG), and E1-A4 (5’-GTTAGATGATGCTACAGTGCC)
with E1–B5 primer. Cycling parameters consisted of initial
denaturation for 5 minutes at 95uC, 40 cycles of 30 seconds of
denaturation at 95uC, 45 seconds of annealing at 55uC, 1 minute
of elongation at 72uC with final elongation of 7 minutes at 72uC.
The primers L1–2, from Bhattacharjee et al. [15] were replaced
with Alt16L1-F (5’-AGGTCGTGGTCAGCCATTAG) and
Alt16L1-R (5’-GGGGATCTTCTTTAGGTGCTG). Cycling pa-
rameters were: initial denaturation for 2 minutes at 95uC, 35
cycles of 20 seconds of denaturation at 95uC, 20 seconds of
annealing at 63uC, and 50 seconds elongation at 72uC with final
elongation of 7 minutes at 72uC. All PCR reactions (50ml)
contained GOTaq-green-PCR-buffer (Promega), 3000mM MgCl2,
100mM each dNTP, 0.2mM of each primer, 50ng sample DNA
and 1U GOTaq-polymerase (Promega). Amplicons were purified
using Promega system as above and sequenced using forward and
reverse primers at the ABI PRISM 310 Genetic Analyzer (Applied
Biosystems, USA) at the Rudjer Boskovic Institute (Zagreb,
Croatia) core facility.
Amplicon sequences were aligned with the reference sequence
using Bioedit version 7.0.5.2. Continuous sequences of variant
samples ZG01-118 and ZG01-258 were created for the E1-
1374 6ˆ3nt E-G350 variant. Continuous sequences of variant
samples ZG03-145 and ZG05-249 were created for the E1-
1374 6ˆ3nt E-C109/G350 variant.
E1 Region Sequencing
The same primers that were used for the whole genome
sequencing of the E1 region (above) were used to sequence the E1
region of 10 additional E1-1374 6ˆ3nt E-G350 variants and 4
additional E1-1374 6ˆ3nt E-C109/G350 variants.
Nomenclature of Variants and Reference HPV16 Genome
The particular variant names used in this study were chosen
according to the proposed HPV16 variant nomenclature [16].
Briefly, variants are named according to their lineage (E, AA, As,
NA1, Af1, Af2) followed by the variant class (only for non
European variants) and the subclass that corresponds to nucleo-
tide(s) present at specified position(s) that are different from the
respective reference sequence; i.e. E-G350 corresponds to the
European lineage variant with G at position 350. The HPV16R
reference sequence was obtained from Papillomavirus Episteme, a
specialized information database for Papillomaviridae family of
viruses (http://pave.niaid.nih.gov/). Other variant reference
sequences were obtained from NCBI GenBank database (http://
www.ncbi.nlm.nih.gov/): AA variant (AF402678), Af1 (AF536180)
and Af2 (AF472509). Sequences and alignment of previously
published whole genomes of HPV16 variants [17] were kindly
provided by Prof R.D. Burk.
E1 HPV16 Variants
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A classification scheme based on full genome analysis has been
recently proposed [17–19]. Using the same approach, we have
classified the variants sequenced in this study to assess to which
lineage or sub lineage they belong (according to their full genome
sequence) and compared them with the previously published
whole genome sequences [17]. The MEGA version 5.05 [20]
software package was used to create maximum likelihood trees and
to calculate pairwise nucleotide sequence differences between each
isolate and all others.
Structural Prediction of the E1 Protein
The three dimensional structures of the variant and the
reference E1 protein were determined from the respective full
length amino acid sequences with three different structure
prediction web servers, SAM-T08 [21], I-TASSER [22] and
Phyre2 [23], based on automated homology modelling. The
resulting models were visualized and analyzed using the Chimera
software [24]. The most likely predicted models were compared to
and superimposed over the already solved partial structures of the
E1 protein deposited in the protein data bank (PDB) under PDB
IDs: 2GXA [25], 1TUE [26] and 1F08 [27]. The I-TASSER
server has additionally been used to optimize the E1 referent
predicted structure using the Phyre2 E1 variant model as a
constraint.
Statistical Analysis
The standard Chi-square (x2) test was used to study associations
between two variables and was calculated using GraphPad Prism
(version 4.00) (GraphPad Software, San Diego, California, USA).
The significance level was set to p,0.05.
Results
The HRM analysis of the E6 amplicon was successful in 722 of
786 (91.9%) individual samples. The European lineage G350
variant (E-G350) was identified by HRM analysis in 358 (51.4%)
cases, while those of the European prototype T350 (E-r) were
found to occur in 212 (30.4%) cases. Two samples had melting
profiles of a mixed infection of E-G350 and E-r variants. In
addition, 150 samples had discrepant or completely different
melting profiles of the E6 region and were, therefore, sequenced to
identify the exact variants. There were 16 samples positive for the
E6 analysis that did not give discernible E1 amplicons. These
samples, which probably have partial disruptions of the E1 region
Table 1. Distribution of the HPV16 variants within different grades of cervical lesions.
Patient cytological diagnosis a
E1 status Variant group b No. c U NC ASCUS LSIL (%) HSIL (%)
E1-1374ˆ63nt
variant
E-G350 46 3 0 9 16 (34.8%) 18 (39.1%)
E-G350 other 5 0 0 1 2 (40%) 2 (40%)
E-C109/G350 22 2 0 3 4 (18.2%) 13 (59.1%)
Subtotal E1 variant 73 5 0 13 22 (30.1%) 33 (45.2%)
E1 reference E-r 220 18 1 36 45 (20.5%) 120 (54.5%)
E-r other 20 1 0 5 5 (25%) 9 (45%)
E-G350 319 29 2 56 67 (21%) 165 (51.7%)
E-G350 other 39 2 1 6 5 (12.8%) 25 (64.1%)
E-C109/G350 9 1 0 3 0 (0%) 5 (55.6%)
E-G131/G350 6 1 0 0 1 (16.7%) 4 (66.7%)
E-G350+ E-r 3 0 0 0 0 (0%) 3 (100%)
Subtotal E 616 52 4 106 123 (20%) 331 (53.7%)
NA1-b/r 8 1 0 1 3 (37.5%) 3 (37.5%)
NA1 other 2 0 0 0 0 (0%) 2 (100%)
AA-a/r 2 0 0 1 1 (50%) 0 (0%)
Af1-b/r 3 0 0 2 0 (0%) 1 (33.3%)
Af2-a/C109/G403 1 1 0 0 0 (0%) 0 (0%)
Subtotal Non-E 16 2 0 4 4 (25%) 6 (37.5%)
Subtotal E1 reference 632 54 4 110 127 (20.1%) 337 (53.3%)
Total 705 59 4 123 149 (21.1%) 370 (52.5%)
aU, unknown diagnosis; NC, normal cytology; ASCUS, atypical squamous cells of undetermined significance; LSIL, low grade squamous intraepithelial neoplasia; HSIL,
high grade squamous intraepithelial neoplasia.
bvariant names according to the recently proposed nomenclature [16]; E-G350 other, all other variants containing 350G and other variations but found in less than 5
samples each; E-r other, all other variants containing 350T with other variations.
cNo., number of samples.
dthis was statistically significant in comparison to E1 reference E-r (p = 0.0227), E1 reference E-G350 (p = 0.0326), E1 reference subtotal E (p = 0.0128) and subtotal E1
reference samples (p = 0.0143).
ethis was statistically significant in comparison to E1 reference subtotal E (p = 0.0452) and borderline significant in comparison with subtotal E1 reference samples
(p = 0.0503).
doi:10.1371/journal.pone.0041045.t001
E1 HPV16 Variants
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due to integration or other rearrangement events, were excluded
from further analysis.
As the HRM method was previously found to be accurate for
viral variant detection [11], only twenty more randomly selected
E-G350 and E-r samples (10 each), chosen as control samples,
were sequenced. Both strands of DNA were sequenced to avoid
sequencing artefacts and such sequencing of the control samples
confirmed the HRM findings in each case (data not shown). The
resulting sequences were grouped and named according to the
proposed nomenclature [16]. Variants that were found in less than
5 samples each, were grouped with the most similar variants and
suffixed with "other" to indicate the presence of other nucleotide
changes (E-r other, E-G350 other, NA1 other) (Table 1). The
exact sequences of 126 samples that contained variations in the
E6, other than the most common G350 variation, are presented in
Supplement material (Table S1). The total prevalence of the E-
G350 variant, including samples with discrepant HRM findings
that were subsequently sequenced, was 52.1% (376/722), while E-
r was found in 31.2% (225/722) samples.
The E1 amplification was successful in 736 samples (93.6%).
There were 30 samples positive for the E1 analysis (PCR amplicon
size 189), which were also repeatedly negative for the E6 analysis
(HRM amplicon size 523 bp), probably due to the degradation of
the DNA. Those samples were excluded from further analysis as
well as one sample containing both referent and variant E1
amplicon.
The combined findings, covering 705 individual samples with
successful E1 and E6 analysis complemented with patient
cytological diagnosis, are presented in Table 1. The E1-
1374 6ˆ3nt duplication was found in only two abundant variant
groups, E-G350 and E-C109/G350, and in 5 other sporadic
variants related to the E-G350 variant (E-G310/G350, E-T91/
G350/C432, E-G350/C473, E-C176/G350, E-T246/G350).
The common feature of all variant groups with the E1-
1374 6ˆ3nt duplication is that they are related to the E-G350
variant. Even though a large number of samples was examined, all
samples contained both the G350 change and the E1-1374 6ˆ3nt
duplication; this exclusive association was highly significant
(x2 = 43.64, p,0.0001). In addition, the E1-1374 6ˆ3nt duplication
was seen only in the European lineage variants. This result might
be influenced by the low number of non-European variants
detected in the Croatian population.
The frequency of high and low grade lesions in different variant
groups and subgroups was examined and compared to the
reference variant (Table 1). Of all the samples in which the
reference variant was found, more than half were diagnosed as
HSIL (120/220; 54.5%) and only 20.5% as LSIL (45/220).
Similar frequencies were found for the E-G350 variant, 51.7% as
HSIL (165/319) and 21% as LSIL (67/319) cases. In contrast, the
E1-1374 6ˆ3nt E-G350 variant (the most common variant with the
E1-1374 6ˆ3nt duplication found in this study) was associated
almost equally with LSIL (16/46; 34.8%) and HSIL (18/46;
39.1%) diagnosis; this association was significant in comparison
with several variant groups that could be considered as a good
reference for comparison (Table 1). Thus, the E1-1374 6ˆ3nt E-
G350 variant was found to be significantly more associated with
lower grade lesions than the E-r variant (x2 = 5.192, p = 0.0227),
the E-G350 variant without the E1-1374 6ˆ3nt duplication
(x2 = 4.565, p = 0.0326), all European lineage samples without
the duplication (x2 = 6.190, p = 0.0128) and all samples without
the duplication (x2 = 5.999, p = 0.0143). The only significant
comparison of all E1-1374 6ˆ3nt variants (Table 1, subtotal E1
variant) were those with all European lineage samples without the
duplication (Table 1, subtotal E [European]; x2 = 4.012,
p = 0.0452), while the comparison with all E1 variants without
the duplication was at the borderline of statistical significance
(Table 1, subtotal E1 reference; x2 = 3.832, p = 0.0503).
Sequencing of the whole genome of two samples with the E1-
1374 6ˆ3nt E-G350 variant revealed a total of 16 common changes
(Table 2; Figure 1). Combined sequences of samples ZG01-118
and ZG01-258 were submitted to the NCBI GenBank and
assigned accession numbers, JN565302 and JN565303, respec-
tively. Combined E1 and E6 analysis has revealed that E1-
1374 6ˆ3nt duplication is also present in the E-C109/G350 variant.
Thus, the whole genomes from two randomly selected samples of
E1-1374 6ˆ3nt E-C109/G350 variant were sequenced, as well.
Combined whole genome sequences of samples ZG03-145 and
ZG05-249 were submitted to the NCBI GenBank and assigned
accession numbers, JQ067943 and JQ067944, respectively
(Table 2; Figure 1).
The full length E1 region sequencing was done on 10 additional
E1-1374 6ˆ3nt E-G350 and 4 additional E1-1374 6ˆ3nt E-C109/
G350 variant samples, and the results are also presented in
Table 2. There was only one additional change within the E1
region (2184 G.A) that was not seen in the full genome
sequences.
Throughout the rest of the whole genome of the E1-1374 6ˆ3nt
E-G350 variant there were 9 additional sites where only a single
sample had a specific nucleotide change. In these cases, 3 more
samples of the E1-1374 6ˆ3nt E-G350 variant were sequenced to
clarify each of these particular regions and derive the consensus
sequence. In all such cases, only one of 5 completely sequenced
samples for each region had the variation, while the other four had
sequences identical to the reference sequence.
The sequences of the E1-1374 6ˆ3nt variant samples were
compared to the previously published HPV16 variant sequences
[17] and notable differences are presented in Figure 1. There are
10 nucleotide changes that are present in both E1-1374 6ˆ3nt
duplication containing variants and the phylogenetically closest
variants (A2 sub-lineage), while E1-1374 6ˆ3nt E-G350 and E1-
1374 6ˆ3nt E-C109/G350 share 14 identical variations. The only
differences between E1-1374 6ˆ3nt E-G350 and E1-1374 6ˆ3nt E-
C109/G350 variants were LCR-G24, E6-C109, E1-C1656 and
E1-T1692. The LCR-G24 and E6-C109 were specific for the E1-
1374 6ˆ3nt E-C109/G350 variant. The E1-C1656 and E1-T1692
were specific for the E1-1374 6ˆ3nt E-G350 variant, but they were
found only in 2 of 12 full length E1 sequences of this variant.
The E1-1374 6ˆ3nt E-G350 variant had only a few changes in
the known oncogenes (Tables 2, Figure 1). In the E6 region there
was only one missense variation, the G350 (L83V) variation, while
E7 region was completely free of variation. However, there were
two missense variations in the E5 oncogene I44L and I65V. The
E4-region was also found to be free of amino acid changes, while
E2, L1 and L2 each had one missense variation common to all
sequenced E1-1374 6ˆ3nt E-G350 variant samples. The sequencing
of the whole genome and additional full length E1 sequences
revealed that all analyzed samples of the E1-1374 6ˆ3nt E-G350
variant had the E1 1053 A.C change and the E1-1374 6ˆ3nt
duplication resulting with the insertion of 21 extra amino acids in
the E1 protein. In addition, there were two silent and one missense
variations, which were found in only a subset of the analyzed
samples.
Phylogenetic analysis has shown that the pairwise difference in
the nucleotide sequences is mostly under 0.5% between all the
European-lineage samples compared. The European (or A) lineage
was further subdivided into 3 sublineages (A1-A3) based on the
tree topology and the sequence percent difference, in a manner
similar to that described previously [17–19]. The A1 lineage
E1 HPV16 Variants
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contained the reference HPV16 genome, the A2 lineage contained
the E-G350 related variants including the E1-1374 6ˆ3nt variants
and the A3 lineage contained only the E-G131 variant that
differed the most from other sequences (Figure 1). Due to the
historical significance of the E-G350 variant, the most investigated
member of the A2 sub-lineage (Figure 1), we have decided to use
the tree topology approach in addition to sequence percent
difference in order to better distinguish the E-G350 from the E-r
variants. A similar approach was recently implemented for HPV11
variants [19].
Structural prediction of the variant and the referent E1 proteins
using the SAM-T08 [21], I-TASSER [22] and Phyre2 [23]
services resulted in several models. However, only the E1 Phyre2
model of the E1-1374 6ˆ3nt variant could be reconciled with the
solved structure of the E1 hexamer (PDB ID:2GXA) [25], without
any overlaps between individual E1 monomer structures. The E1
reference protein model was refined by the I-TASSER server
using the Phyre2 E1-1374 6ˆ3nt variant structure as a constraint.
Figure 2 presents the predicted full length structural models of the
reference and the E1-1374 6ˆ3nt variant proteins. From the
structural prediction, it appears that both E1-C1053 and E1-
1374 6ˆ3nt are positioned on the surface of the E1 protein.
Additional three dimensional representations of the predicted
models are presented in Supplement material (Figure S1).
Discussion
In the current study, we have focused on the interesting
observation that the E1-1374 6ˆ3nt variant was unusually common
and, more importantly, that it was significantly associated with low
Table 2. Positions of nucleotide and amino acid changes within the whole genome and E1 sequences of the major HPV16 variants
containing the E1-1374ˆ63 duplication.
Curated referent
sequence position a
Referent
sequence
Nucleotide changes
(number observed/number sequenced) b Description of the variation
E1-1374ˆ63 E-G350
E1-1374ˆ63
E-C109/G350
24 C C (2/2) G (2/2) c Silent
109 T T (2/2) C (2/2) c E6 silent
350 T G (2/2) G (2/2) E6 83 L . V d
1053 A C (12/12) C (6/6) E1 63 E . D d
1374ins - INS (12/12) INS (6/6) E1 duplication of 63 nucleotides
1656 T C (2/12) T (6/6) E1 silent
1692 A T (2/12) A (6/6) E1 276 (297) L . F
2184 G A (1/12) G (6/6) E1
3058 G A (1/5) G (2/2) E2 silent
3410 C T (2/2) T (2/2) E2 219 P.S and E4 silent d
3979 A C (2/2) C (2/2) E5 44 I . L d
4042 A G (2/2) G (2/2) E5 65 I . V d
4211 ins - GTTT (2/2) GTTT (2/2) Silent Insertion of GTTT d
4211 ins - GTT (1/5) - (2/2) Silent insertion of GTT
4228 T C (2/2) C (2/2) Silent d
4234 A C (1/5) A (2/2) Silent
4344 T C (1/5) T (2/2) L2 silent
4563 G T (1/5) G (2/2) L2 silent
4938 G A (2/2) A (2/2) L2 silent d
5223 T G (1/5) T (2/2) L2 329 D.E
5226 A T (2/2) T (2/2) L2 330 L.F d
5518 A C (1/5) A (2/2) L2 428 I.L
6434 A G (2/2) G (2/2) L1 292 T.A d
6753 T C (1/5) T (2/2) L2 398 L.S
7193 G T (2/2) T (2/2) Silent d
7320 A A (2/2) G (1/2) Silent
7338 A C (1/5) A (2/2) Silent
7450 T C (2/2) C (2/2) Silent d
7521 G A (2/2) A (2/2) Silent d
anovel nucleotide changes are highlighted in bold and underlined.
bchanges from the reference are highlighted in bold.
cvariations differentiating E1-1374ˆ63 duplication containing E-G350 and E-C109/G350 variants.
dvariation present in all samples.
doi:10.1371/journal.pone.0041045.t002
E1 HPV16 Variants
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grade lesions [7]. To confirm that this variant is indeed very
prevalent in the Croatian population, we have enlarged the sample
pool to include 822 HPV16 positive cervical specimens. The
prevalence of the E1-1374 6ˆ3nt variant remained about 10%, as
previously determined on a subset of samples [7]. In addition, to
resolve the observed association of the E1-1374 6ˆ3nt variant with
low grade lesions, we had to eliminate the possible influence of
other known variants. For that purpose we have analyzed the
variant status of the E6 oncogene region, which is commonly
analyzed in HPV variability studies. Sequencing of the samples
that were preselected by the HRM clarified the variant status, with
20.8% of samples exhibiting melting curves that differed from the
most common E-G350 and E-r curves. It is important to
emphasize that the HRM analysis was employed only as a pre-
screening tool to avoid repeated sequencing of the wild type or any
other clearly distinguishable and common variant (E-G350 and E-
r). All other samples were sequenced. In this regard, the HRM
proved to be a powerful pre-screening method. Namely, of the
20.8% of samples subjected to sequencing, 79.2% were indeed
identified as new variants. This approach enabled us to conduct
one of the largest studies on HPV16 E6 variants so far.
Comparing the status of the E1-1374 6ˆ3nt duplication and
different groups of E6 variants revealed that it is exclusively
present in the E-G350 and the related variants. Around two thirds
(63%) of all E1-1374 6ˆ3nt cases belonged to the E-G350 variant,
while almost another third (30.1%) belonged to the E-C109/G350
variant (Table 1).
The hypothesis based on our previous study [7], that the
originally identified E1-1374 6ˆ3nt E-G350 variant is more
associated with LSIL lesions than the referent HPV16 variant, is
further supported by data acquired on the substantially larger
number of samples analyzed in the current study. In all
comparisons with other relevant variant groups, the E1-
1374 6ˆ3nt E-G350 variant was statistically significantly less
associated with HSIL and more with LSIL (Table 1).
However, the variant E-C109/G350 with the E1-1374 6ˆ3nt
duplication, identified in this study, is not in line with the previous
hypothesis. Unexpectedly, this variant was more associated with
Figure 1. Phylogenic clustering of E1-1374ˆ63nt variant sequences with other currently available published HPV16 whole genome
sequences. The whole genome sequences of four E1-1374ˆ63nt variant samples (ZG01-118, ZG01-258, ZG03-145 and ZG05-249) were aligned with
the available published whole genome sequences and the phylogenetic tree was created using MEGA5. The leftmost part shows the percent
nucleotide sequence differences calculated using MEGA5 to determine variant lineages according to a proposed taxonomic classification [18,19]. The
top part of the figure was adapted from the transcription map of HPV16 available at http://pave.niaid.nih.gov/. Sequences at respective positions are
shaded in different shades of blue according to the distance from the E1-1374ˆ63nt variant. Dots "." indicate no change from referent sequence while
"," and "INS" indicate insertions. The European (or A) lineage appears to be subdivided into 3 sublineages A1–A3, based on the tree topology and
sequence percent difference similarly as previously described [17–19]. The A1 lineage contains the reference HPV16 genome, the A2 lineage contains
the E-G350 related variants, including the E1-1374ˆ63nt variant samples and the E-12 variant described in Bhattacharjee et al. [15]. The A3 sublineage
contains only the E-G131 sample, which exhibits the most difference from other sequences. Variant "E-12" was previously shown to be more
prevalent in cancer samples [15], while the variation 7450 T.C was shown to be statistically more prevalent in cancer samples [49]. Positions where
samples ZG01-118 and ZG01-258 differ have been sequenced for 3 additional samples and in each case only one of 5 sequenced samples has this
change. Additional whole length E1 sequencing has revealed that changes at positions 1656 and 1692 were only present in 2 of 12 samples. Thus, all
those changes are unlikely to be the major cause of the association of the E1-1374ˆ63nt E-G350 variant with low grade cervical lesions. The major
difference between E1-1374ˆ63nt E-G350 variant and other variants are the positions 1053 and 1374, while the only differences between the E-G350
and E-C109/G350 sequenced variants are at positions 24 and 109.
doi:10.1371/journal.pone.0041045.g001
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HSIL diagnoses (59.1%) than even the reference (E-r) variant
(54.5%) (Table 1). However, this observation might be influenced
by the relatively small number of samples, as there were only 23
E1-1374 6ˆ3nt E-C109/G350 variant samples, and only 9 E1
referent E-C109/G350 variant samples. The E-C109/G350
variant itself was reported in many previous studies but, in almost
every study, this variant was less prevalent than in the current
sample pool, often being found in only 1 or 2 cases [6,12,28–33].
Exceptions can be found in the studies by Wheeler et al. [34] (8 of
67) and Zuna et al. [35] (18 of 354). Even though the E-C109/
G350 variant appears to be rare in most of the populations studied
and thus without major clinical significance, it has been noted in
more than 20 publications worldwide which is a comparable to
AA-a- r, (23 papers), NA-b-r (21 papers) and E-G131/G350 (26
papers), according to the recent comprehensive review on HPV16
variants [16]. This widespread presence suggests biological
relevance of this variant, even if it was detected at low prevalence
within most studies.
The full length E1 sequences and the whole genome sequences
of HPV16 E1-1374 6ˆ3nt duplication containing E-G350 and E-
C109/G350 variants revealed a total of 14 deviations from the
reference HPV16 sequence, common for both variants, and 2
additional changes that differentiated the E-G350 and E-C109/
G350 variants (indicated in Table 2 with superscript letters d and c,
respectively, and Figure 1). Variations at positions 1656 and 1692
were only detected in two whole genome sequences and not in 10
additional full E1 sequences and are thus considered not
significant. There were 13 additional deviations found throughout
Figure 2. Prediction of E1 protein structure. Panel A shows 3D structure comparison between superposed monomer of the previously solved
BPV1 E1 helicase domain hexamer structure (cyan; PDB ID:2GXA) [25], HPV18 E1 helicase domain structure (yellow; PDB ID:1TUE) [26], BPV1 E1 DNA
binding domain structure (red; PDB ID:1F08) [27] and the predicted referent E1 model (white). The sequence at the position where the duplication
occurs within the E1-1374ˆ63nt variants is highlighted in green, as is the amino acid 63 that is also changed in the E1-1374ˆ63nt variants. Panel B
depicts superposed structures of the referent (white) and E1-1374ˆ63nt variant (magenta) E1 models. As before the referent sequence is highlighted
in green and the changes specific to E1-1374ˆ63nt variant are highlighted in red. It can be seen that the newly added 21 amino acids (highlighted in
red) partially overlap the potentially phosphorylated threonines (highlighted in green) at positions 153 and 155 and possibly influence the
phosphorylation regulation of the E1 function. Panels C and D show the hexamer structure derived from the predicted E1 reference or E1-1374ˆ63nt
variant proteins, respectively. The individual monomers are colored differently. The original referent sequence is colored in green within the white
referent E1 monomer and the E1 variant magenta monomer. The sequence duplication in the E1-1374ˆ63nt variants is located at the junction
between 2 adjacent E1 monomers within the structure and is highlighted in red on panel D. Positions of potentially phosphorylated threonines and
amino acid substitution at position 63 are only highlighted on the white and magenta monomers.
doi:10.1371/journal.pone.0041045.g002
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the genomes that were present only in a subset of sequenced
samples (Table 2).
Of all changes from the reference found in the HPV16 E1-
1374 6ˆ3nt variant, the 350 T.G change has been reported most
often. Some studies linked 350 T.G to higher oncogenic potential
or viral persistence [36–41], but others did not [30,33,35,42–44].
In addition, recent in vitro functional studies indicated advantages
of this E-G350 variant over the reference HPV16 [45,46], while
another study found no difference between them [47]. In the
current study, the E-G350 variant was slightly less associated with
HSIL (51.7%) than the reference variant (54.5%). However, each
of the E-G350 related variants (E-C109/G350, E-G350 other and
E-G131/G350) were more associated to HSIL (55.6%, 64.1% and
66.7%, respectively) than the reference variant (Table 2). In either
case, the consistent presence of change 350 T.G in the E1-
1374 6ˆ3nt E-G350 variant is unlikely to be able to significantly
decrease the association with HSIL of this variant or increase it
with LSIL.
There have been many studies analyzing parts of the HPV16
genomes, and listing them all would exceed the scope of this paper.
However, the majority of variations of the whole genome found
within the E1-1374 6ˆ3nt variants in this study were also found in
four studies that sequenced the whole genomes of 7 [32], 12 [48],
62 [17] and 98 samples [15]. These four studies detected 20 of 29
variations found in the E1-1374 6ˆ3nt variant and the majority of
variations were observed in all 4 studies. The E1-1374 6ˆ3nt E-
G350 variant samples have a similar profile to the 9 phylogenet-
ically closest sequences, which exhibit changes from the reference
at positions 350, 3410, 3979, 4042, 4228, 4938, 5226, 6434, 7193
and 7521 (Figure 1). This combination of variations, with an
additional change at the position 7450, which is also specific for
the E1-1374 6ˆ3nt variant, was previously described by Bhatta-
charjee et al. [15] to be the most prevalent variant in the Indian
population and this specific variant was named E-12. More
interesting is the report that the change 7450 T.C, within the
LCR, is associated with cervical cancer [49]. The Indian variant
E-12, that contains 7450 T.C change, was more prevalent in
cancer cases than controls (38.2% vs. 28.5%); however, this was
not statistically significant [15]. In any case, the Indian variant E-
12 was more prevalent in cancer, and the 7450 T.C change
significantly more so, making it unlikely that any of those changes
(350, 3410, 3979, 4042, 4228, 4938, 5226, 6434, 7193, 7521 and
7450) could be responsible for the association of the E1-1374 6ˆ3nt
E-G350 variant with lower grade lesions.
Within the whole genome, only 9 more novel changes in the E1-
1374 6ˆ3nt E-G350 variant were identified (Table 2). Of those, 7
are found in a small subset of tested samples, making them unlikely
to be responsible for the observed association with lower grade
cervical lesions. The remaining 2 changes are the E1-1374 6ˆ3nt
duplication itself and the 1053 A.C change, which leads to the
substitution 63 E.D in the E1 protein. This change, along with
the E1-1374 6ˆ3nt duplication, might affect the H1 histone, the
DNA binding, the E1 protein oligomerization [50] or the
regulation of the E1-E2 interaction [51]. Most of the functional
studies on E1 were done on the BPV1 and HPV11 E1 proteins
but, according to the review by Sverdrup and Myers [52], the E1
protein appears to be well conserved in sequence, structure and
function. Lentz et al. [53] found Tyr126 within BPV E1 to be
phosphorylated, while sequence alignment by Sverdrup and Myers
[52] revealed no tyrosine at position 126 within the HPV16 E1.
However, two tyrosine residues were found at 5 and 7 amino acid
positions downstream, exactly within the region that is duplicated
in the E1-1374 6ˆ3nt variants. Thus, we can speculate that the
duplication might influence the phosphorylation of the HPV16 E1
protein as well, especially because it is known that the N-terminal
part of the protein is involved in the regulation of the E1 function
[50]. Furthermore, from the predicted structural model of the E1
proteins (Figure 2), it appears that this position is on the surface of
the protein, making it accessible to phosphorylation. However,
within the E1-1374 6ˆ3nt variants, the newly added 21 amino acids
overlap the positions of potentially phosphorylated tyrosines
(Figure 2D) making them probably less accessible. The newly
added tyrosines are situated at almost the opposite part of the same
loop (Figure 2D, coloured in red) and might not be phosphorylated
or their phosphorylation might not have the same effect on the E1
protein. In addition, we can speculate that the gain of these 21
amino acids might sterically hinder oligomerization of the E1
protein or alter other protein interactions. The change 63 E.D
(glutamate to aspartate) was also predicted to be situated at the
surface of the protein (Figure 2B, 2D) and might also be involved
in E1 protein-protein interactions. However, any influence the E1-
1374 6ˆ3nt duplication might have does not seem to have a drastic
effect on the pathogenicity of this HPV16 variant. Namely, the
duplication is still found in HSIL lesions, albeit less often. In this
light, it is not unexpected that we found no drastic changes in the
function of the E1 protein or in the predicted structure.
From the evolutionary perspective, it appears that the E1-
1374 6ˆ3nt E-G350 variant appeared among the HPV16 European
lineage A2 sub-lineage variants, as it shares many variations with
this sub-lineage (Figure 1). The initial events that occurred appear
to be the addition of the 1053C and the 1374 6ˆ3nt changes within
the E1 region, the GTTT insertion within the non-coding region
at position 4211, and the 7450A change within the LCR. It is
interesting that the A2 sub-lineage like variants containing the
4211 GTTT insertion and the LCR 7450A changes are common
within the Indian population [15], thus the E1 1374 6ˆ3nt specific
branching is likely to have initially occurred within such sub-
lineage. Following this first evolutionary branching, the E1
1374 6ˆ3nt sub-lineage later split again with one branch acquiring
additional LCR 24G and E6 109C changes. From the sequence
analysis in this study, it appears that both sub-branches evolved
separately and individually acquired further variations, however,
as we found less variations within the 109C branch and this
branch was present in fewer samples we can speculate that this
109C branch is more recent on the evolutionary scale. When
considering our findings in the evolutionary context, we note that
the usual A2 sub-lineage variants, historically represented by the
E-G350 and the related variants, have never been previously
associated with reduced cervical cancer risk or lower grade cervical
lesions, but have been often associated with higher cancer risk [2].
However, after the E1 1374 6ˆ3nt branching, the association of the
E1 1374 6ˆ3nt E-G350 with the lower grade cervical lesions was
shown to be statistically significant, at least in comparison with the
E-r variant and the E-G350 variants, the most common variants in
the Croatian and many other populations worldwide [28]. From
these phylogenetic considerations we can again conclude that
changes within the E1 region might probably be the cause of the
observed association.
The lack of obviously significant differences between different
E1-1374 6ˆ3nt variants, E-G350 and E-C109/G350 was surprising.
The only differences were the silent variations at position 24 C.G
within the LCR and 109 T.C within the E6 region. To
understand the possible significance of these variations, we
reviewed the current literature searching for any potential effects
these changes might have and found several possible mechanisms.
The LCR region has been extensively studied for binding sites
of different cellular and viral factors important for HPV
replication and transcription regulation (extensively reviewed in
E1 HPV16 Variants
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[54–57]). Position 24 itself is not within the binding site of any
known transcription factors. However, it is located in the
immediate vicinity of two potential binding sites, one for AP1
(nucleotides 15–21) and the other for SP1 (nucleotides 28–33). It is
possible that, while the optimum consensus sequences of those
transcription factors span only those mentioned positions, the
transcription factor binding can be slightly influenced by a longer
stretch of sequence.
The 109 T.C change is the signature variation of the E-C109/
G350 variant. Position 109 is situated within the second codon of
the 151 amino acid form of the E6 protein [58] but does not
change the amino acid sequence of the E6 protein. This position is
also interesting as it is in the immediate vicinity of the LCR region,
which has always been investigated up to the promoter P97,
although no sequence has thus far been analyzed for potential
transcription factor binding sites after this position. However, the
underlined sequence after the bolded start codon of the E6
protein, ATG?TTT?CA, corresponds to the AP1 factor binding
site consensus (T[G/T]?[A/T]NT?[A/C]A) and almost perfectly
to the predicted optimum sequence TG?ANT?CA (the only
mismatch is underlined) [54]. We believe that this AP-1 site is
actually capable of binding AP-1 transcription factor as the exact
same sequence TG?TTT?CA is found in the ARRE-2 region of
the human interleukin 2 promoter and is even conserved in birds
[59]. In addition, the ARRE-2 site has been shown to be able to
promote transcription when binding AP-1, even without other
regulatory elements of the human interleukin 2 promoter [60].
The 109 T.C change corresponds to the sequence
ATG?TTC?CA, which disrupts the consensus sequence that was
found to accept only T in all oligonucleotides that bind AP1 at that
changed position. Furthermore, it is known that HPV preferen-
tially uses codons that are not optimal in its human host (reviewed
in [61]). One of the reasons for this is probably to avoid the host
immune response by reducing the production of viral proteins
[62]. In this case, the 109 T.C substitution changes the
phenylalanine codon TTT to the only other phenylalanine codon
TTC. However, the TTT codon is preferentially used by the HPV
(45.5/1000 codons) and not so by the human host (15.8/1000
codons), while the TTC codon is rarely used by HPV (only 4.0/
1000 codons) but more commonly used by the human host (22.6/
1000 codons) [63]. The confirmation that codon usage affects the
HPV protein expression is the study by Cid-Arregui et al. [64] who
showed that the codon optimized E7 protein is expressed 20–100
times more than the wild type HPV16 E7, and that the major
difference was significantly improved translation. Another piece of
evidence that the TTT codon might be suboptimal in E6
expression is from the study of Looman et al. [65], who show
that it is the least optimal second codon of 31 possible second
codons tested in a yeast expression system, with a 5.3 fold
difference from best to worst. There are findings indicating that
second codon can influence the efficiency of recognition of the
start codon during translation. Phenylalanine that is situated at the
second codon was rarely found in human proteins at that position
[66,67], suggesting that HPV might be using a suboptimal
sequence to again reduce the protein levels in spite of strong
enhancers [68]. That the second codon position is important, is
also confirmed by the demonstration that codons at the 5’ end of
the mRNA can be rate limiting factors in protein synthesis [69]
and can also influence premature translation termination [70]. In
addition to directly repressing E6 protein translation, phenylala-
nine as the second codon could also be involved in E7 translation,
as it appears that leaky scanning of E6/E7 bicistronic mRNA is
the predominant mechanism of E7 translation [71]. The final
possible mechanism involves translation frameshifting, as was
shown in the study of Fu and Parker [72]. The authors showed
that the sequence UUU?(U/C) can be misread by the ribosome so
that instead of reading nucleotides 1 to 3 (UUU), nucleotides 2 to 4
are instead read UU?(U/C) as phenylalanine. In essence, this
introduces a 1 bp deletion and a corresponding frameshift, which
truncates the protein [72]. The frequency of such a frameshift was
found to be 3–16% in the studied argI mRNA translation [72].
However, in the mutated sequence UUC?(U/C), this frameshift
cannot take place. The same situation is found in the HPV16
sequence where UUU?C is changed in the E-C109 variant into
UUC?C making the frameshift permissive sequence into an
unpermissive sequence, again possibly influencing the E6 protein
synthesis.
From all these studies it appears that the seemingly insignificant,
silent change 109 T.C can very possibly affect the viral oncogene
expression and its regulation, which probably influences viral life
cycle and oncogenic potential of the E-C109/G350 and related
variants. These direct changes to oncogene levels would very
probably negate any effects of the E1 changes seen in the E1-
1374 6ˆ3nt E-C109/G350 variant.
During the preparation of this manuscript, a report on E1-
1374 6ˆ3nt variant was published by Bogovac et al. [8] from
neighbouring Slovenia. The authors evaluated the prevalence of
the variant containing the same 63 nucleotide duplication within
the E1 region in 390 HPV16 positive cervical samples ranging
from normal cytology to cervical cancer. The E1- 1374 6ˆ3nt
variant was found by RT-PCR in 31/390 (8%) samples, making its
prevalence in Slovenia lower but still very close to the Croatian
prevalence of this variant. Bogovac et al. [8] sequenced only the
E6 region of the E1- 1374 6ˆ3nt variant samples and only from
nucleotide 273 to nucleotide 441 of the HPV16 genome to
confirm the E-G350 association. Thus, it was not possible to
compare our studies regarding the E1- 1374 6ˆ3nt E-C109/G350
variant. The authors did see some trend of decreasing prevalence
of E1- 1374 6ˆ3nt variant from 14.6% in normal cytology samples
to 7.1% in cancer samples, but without statistical significance.
Bogovac et al. [8] confirmed their E1 RT-PCR results by
sequencing and found the exact duplicated sequence within the
E1 as we see in Croatian samples. However, as they sequenced
only a 161 bp fragment of the E1 region (1258 to 1277) it is
impossible to determine if their samples also contain any of the
other E1 variations described in the current study.
In summary, we have found no significant changes in the whole
genome of the E1-1374 6ˆ3nt E-G350 variant that differentiate this
variant from the A2 sub-lineage variants, except in the E1 region.
Thus, our findings indicate that E1 changes might significantly
affect the virus, especially considering the essential role of the E1
protein in viral replication. However, further functional studies are
required to elucidate the exact impact of these changes on the
protein itself and its functions. The thorough research of the E1
gene variability, that was thus far neglected, definitely should be
considered in future HPV16 variability studies. The current study
indicates that variations in the E1 region might have an impact on
the virus and therefore might affect the findings of studies
investigating epidemiological association of variants and disease.
This was most evident for the frequently studied 350 T.G
variation, since the E1-1374 6ˆ3nt duplication is exclusively linked
with this variation. The analysis of the E6 region alone, without
consideration for the E1 region, could have confounded the
results. Specifically, the exclusion of the E1 region analysis in the
variability studies might be the cause for the current conflicting
results, in the published literature, regarding the E-G350 variant
and possibly the specific E-12 variant common in the Indian
population. The unexpected finding in this study was the E1-
E1 HPV16 Variants
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1374 6ˆ3nt E-C109/G350 variant that was more associated with
the high grade lesions than almost all other variants. From this
study and the results found in the literature on the possible effects
of the 109 T.C variation, it appears that this is not just an
insignificant silent change but, on the contrary, affects several
mechanisms of the viral life cycle. The E-C109/G350 variant
definitely deserves more thorough study, especially in the light of
its worldwide distribution and association with high grade cervical
lesions.
Supporting Information
Figure S1 Prediction of E1 protein structure. Panels A
and C depict two different views of the 3D structure superposed
comparison between a monomer of the previously solved BPV1
E1 helicase domain hexamer structure (cyan; PDB ID:2GXA)
[25], HPV18 E1 helicase domain structure (yellow; PDB
ID:1TUE) [26], BPV1 E1 DNA binding domain structure (red;
PDB ID:1F08) [27] and the predicted referent E1 model (white).
The sequence at the position where the duplication occurs within
the E1-1374 6ˆ3nt variants is highlighted in green, as is the amino
acid 63 that is also changed in the E1-1374 6ˆ3nt variants. Panels B
and D depict two different views of the superposed structures of
the referent (white) and the E1-1374 6ˆ3nt variant (magenta) E1
models. The referent sequence is highlighted in green and the
changes specific to E1-1374 6ˆ3nt variant are highlighted in red.
Panels E and F show two views of the E1 helicase domain hexamer
structure (cyan; PDB ID:2GXA) with both E1 reference and E1-
1374 6ˆ3nt variant structures superimposed on a single monomer of
the solved structure.
(TIF)
Table S1 Sequencing findings of the samples with
unusual melting curves and the effect of specific
variations on the 151 amino acid form of the E6 protein.
(XLS)
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